Work

Supplementary Methods from A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: PDF file, 84KB.

DOI: 10.1158/1078-0432.22446678.v1

Authors: David S. Hong, Daniel W. Bowles, Gerald S. Falchook, Wells A. Messersmith, Goldy C. George, Cindy L. O'Bryant, Alex C. H. Vo, Kevin Klucher, Roy S. Herbst, S. Gail Eckhardt, Scott Peterson, Diana F. Hausman, Razelle Kurzrock, Antonio Jimeno

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361903615

Cites:

Cited by:

Related to: 10